{"Clinical Trial ID": "NCT00190671", "Intervention": ["INTERVENTION 1:", "Pemetrexed 600mg/m2", "Pemetrexed: 600 mg/m2, intravenous, 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, 21 days x 8 cycles", "INTERVENTION 2:", "Pemetrexed 1800mg/m2", "Pemetrexed: 1800 mg/m2, intravenous, 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, 21 days x 8 cycles"], "Eligibility": ["- You must be a woman and at least 18 years of age. - You must have been diagnosed with breast cancer. - Your laboratory tests before the study meet the requirements of the study. - You must be prepared to take folic acid and vitamin B12. Exclusion criteria: - You are pregnant or breast-feeding. - You have another disease that your doctor thinks will make you unable to participate. - You are currently taking aspirin or aspirin-like medications and cannot stop for a few days during each treatment cycle."], "Results": ["Performance measures:", "Best tumour response", "The tumour response was evaluated using radiological imaging, which was repeated every 6 weeks before each other cycle. Confirmation of the response was expected to occur at least 4 weeks (28 days) after the first evidence of response.", "Time frame: basis for measuring progressive disease", "Results 1:", "Title of arm/group: Pemetrexed 600mg/m2", "Description of the arm/group: Pemetrexed: 600 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles", "Total number of participants analysed: 42", "Type of measurement: Number", "Unit of measure: Participants Complete response: 0", "Partial reply: 8", "Stable disease: 18", "Progressive diseases: 13", "Unknown: 3", "Not evaluated: 0", "Results 2:", "Title of the arm/group: Pemetrexed 1800mg/m2", "Description of the arm/group: Pemetrexed: 1800 mg/m2, intravenous, every 21 days x 8 cycles Cyclophosphamide: 600 mg/m2, intravenous, every 21 days x 8 cycles", "Total number of participants analysed: 61", "Type of measurement: Number", "Unit of measure: Participants Complete response: 0", "Partial reply: 20", "\u2022 Stable disease: 26", "Progressive diseases: 8", "Unknown: 5", "Not evaluated: 2"], "Adverse Events": ["Undesirable Events 1:", "Total: 6", "Agranulocytosis 0/42 (0.00 %)", "Anemia 2/42 (4.76%)", "Febrile neutropenia 1/42 (2.38%)", "- Leucopenia 0/42 (0.00 %)", "Neutropenia 1/42 (2.38 %)", "Thrombocytopenia 1/42 (2.38 %)", "Cardiorespiratory arrest 0/42 (0.00 %)", "1/42 (2.38%)", "Gastric ulcer haemorrhage 0/42 (0.00 %)", "Melaena 0/42 (0.00 %)", "Fatigue 1/42 (2.38 per cent)", "- Multi-organ failure 0/42 (0.00 per cent)", "Adverse Events 2:", "Total: 13", "Agranulocytosis 1/61 (1.64%)", "Anemia 1/61 (1.64%)", "Febrile neutropenia 0/61 (0.00 %)", "Leucopenia 2/61 (3.28%)", "Neutropenia 2/61 (3.28%)", "Thrombocytopenia 1/61 (1.64%)", "Cardiorespiratory arrest 1/61 (1.64%)", "Pericardial infusion 0/61 (0.00 %)", "Haemorrhage of gastric ulcer 1/61 (1.64%)", "Melaena 1/61 (1.64%)", "Fatigue 1/61 (1.64%)", "- Multi-organ failure 1/61 (1.64%)"]}